These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 19810877)

  • 1. Rasagiline: an anti-Parkinson drug with neuroprotective activity.
    Youdim MB
    Expert Rev Neurother; 2003 Nov; 3(6):737-49. PubMed ID: 19810877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives.
    Mandel S; Weinreb O; Amit T; Youdim MB
    Brain Res Brain Res Rev; 2005 Apr; 48(2):379-87. PubMed ID: 15850677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition.
    Youdim MB; Bar Am O; Yogev-Falach M; Weinreb O; Maruyama W; Naoi M; Amit T
    J Neurosci Res; 2005 Jan 1-15; 79(1-2):172-9. PubMed ID: 15573406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline.
    Youdim MB; Maruyama W; Naoi M
    Drugs Today (Barc); 2005 Jun; 41(6):369-91. PubMed ID: 16110345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway.
    Weinreb O; Amit T; Bar-Am O; Chillag-Talmor O; Youdim MB
    Ann N Y Acad Sci; 2005 Aug; 1053():348-55. PubMed ID: 16179541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline.
    Bar-Am O; Weinreb O; Amit T; Youdim MB
    J Neurochem; 2010 Mar; 112(5):1131-7. PubMed ID: 20002521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline.
    Youdim MB; Amit T; Falach-Yogev M; Bar Am O; Maruyama W; Naoi M
    Biochem Pharmacol; 2003 Oct; 66(8):1635-41. PubMed ID: 14555244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation.
    Bar-Am O; Amit T; Weinreb O; Youdim MB; Mandel S
    J Alzheimers Dis; 2010; 21(2):361-71. PubMed ID: 20555137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].
    Youdim MB; Weinstock M
    Cell Mol Neurobiol; 2001 Dec; 21(6):555-73. PubMed ID: 12043833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease.
    Chen JJ; Swope DM
    J Clin Pharmacol; 2005 Aug; 45(8):878-94. PubMed ID: 16027398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline.
    Bar Am O; Amit T; Youdim MB
    Neurosci Lett; 2004 Jan; 355(3):169-72. PubMed ID: 14732458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease.
    Avramovich-Tirosh Y; Amit T; Bar-Am O; Zheng H; Fridkin M; Youdim MB
    J Neurochem; 2007 Jan; 100(2):490-502. PubMed ID: 17144902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.
    Naoi M; Maruyama W
    Expert Rev Neurother; 2009 Aug; 9(8):1233-50. PubMed ID: 19673610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
    Fernandez HH; Chen JJ
    Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease?
    Blandini F
    CNS Drug Rev; 2005; 11(2):183-94. PubMed ID: 16007239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo.
    Bar-Am O; Yogev-Falach M; Amit T; Sagi Y; Youdim MB
    J Neurochem; 2004 Jun; 89(5):1119-25. PubMed ID: 15147504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.